Eva Frei
- Pharmacology top 0.05%
- Pharmacogenetics and Drug Metabolism 58
- Drug-Induced Hepatotoxicity and Protection 31
- Analytical Chemistry top 0.2%
- Cancer Research top 2%
- Carcinogens and Genotoxicity Assessment 32
-
- Nephrotoxicity and Medicinal Plants 30
- Oncology top 2%
- Drug Transport and Resistance Mechanisms 26
- Cancer Treatment and Pharmacology 17
-
- Cancer therapeutics and mechanisms 46
- Glutathione Transferases and Polymorphisms 18
Eva Frei
226 papers receiving 5.6k citations
Peers
Comparison fields: 5 of 139
- Pharmacology 2.1k
- Analytical Chemistry 909
- Cancer Research 879
- Radiology, Nuclear Medicine and Imaging 1.1k
- Oncology 1.3k
Countries citing papers authored by Eva Frei
This map shows the geographic impact of Eva Frei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Frei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Frei more than expected).
Fields of papers citing papers by Eva Frei
This network shows the impact of papers produced by Eva Frei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Frei. The network helps show where Eva Frei may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Eva Frei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 10 | |
| 2 | 2014 | 22 | |
| 3 | 2013 | 50 | |
| 4 | 2012 | 58 | |
| 5 | 2012 | 25 | |
| 6 | 2010 | 29 | |
| 7 | 2008 | 3 | |
| 8 | 2007 | 100 | |
| 9 | 2006 | 7 | |
| 10 | 2005 | 109 | |
| 11 | 2003 | 30 | |
| 12 | 2002 | 71 | |
| 13 | 2002 | 34 | |
| 14 | 2002 | 50 | |
| 15 | Targeting of Ellipticine Drugs on Tumor Cells | 2001 | 1 |
| 16 | Aristolochic Acids and a Renal Disease - Chinese Herbs Nephropathy | 2000 | 2 |
| 17 | 1997 | 59 | |
| 18 | 1992 | 14 | |
| 19 | 1987 | 4 | |
| 20 | Phase I and phototoxicity studies of pseudourea (NSC-56054). | 1971 | 3 |
About Eva Frei
Eva Frei is a scholar working on Pharmacology, Biochemistry, Analytical Chemistry, Cancer Research and Oncology, having authored 231 papers that have together received 5.8k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (58 papers), Cancer therapeutics and mechanisms (46 papers), Carcinogens and Genotoxicity Assessment (32 papers), Drug-Induced Hepatotoxicity and Protection (31 papers), Nephrotoxicity and Medicinal Plants (30 papers), Drug Transport and Resistance Mechanisms (26 papers), Glutathione Transferases and Polymorphisms (18 papers) and Cancer Treatment and Pharmacology (17 papers). The work is most often cited by research in Pharmacology (2.1k citations), Analytical Chemistry (909 citations), Cancer Research (879 citations), Radiology, Nuclear Medicine and Imaging (1.1k citations) and Oncology (1.3k citations). Eva Frei has collaborated with scholars based in Germany, Czechia and United Kingdom. Frequent co-authors include Marie Stiborová, Heinz H. Schmeiser, Manfred Wießler, Volker M. Arlt, Petr Hodek, Václav Martínek, Jitka Poljaková, David H. Phillips, Christian A. Bieler and René Kizek. Their work appears in journals such as Cancer Letters, Chemical Research in Toxicology, Carcinogenesis, Biochemical Pharmacology and Toxicology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.